Hims & Hers (NYSE:HIMS) was supposed to be one of the losers due to the semaglutide shortage ending. However, it has bottomed out and surged after the company announced a partnership with Novo Nordisk (NYSE:NVO). NVO stock also cratered in recent months, so this is a win-win.
While a 35% single-day gain might make potential investors hesitant to jump in, analyst sentiment and price targets suggest there could still be significant upside potential for HIMS stock.
This post originally appeared at Money Morning.